CV
Univ. Prof. Dr. med. Johannes Brägelmann
Academic education
10/2014 - 10/2017: Masters program „Biostatistics & Medical Biometry“, University of Heidelberg
10/2005 - 06/2012: Medical School, University of Bonn
Scientific degrees
06/2024 Venia legendi (Habilitation) in “Molecular Medicine” by the Medical Faculty of the University Cologne
10/2017: Master of Science, University of Heidelberg
06/2014: M.D., University of Bonn, Summa cum laude: „RNA-Seq-based investigation of a viral etiology and prognostic analysis of young patients with oral cancer“ (Supervisor: Prof. Dr. Tanguy Seiwert, Department of Hematology/Oncology, University of Chicago & Prof. Dr. Peter Brossart, Department of Oncology, University Hospital Bonn)
06/2012: Graduation from Medical School, University of Bonn
Scientific career
06/2025 - present: Appointment as full Professor for Translational Oncology (W2), University Hospital Bonn, Germany
09/2020 - 05/2025: Junior Research Group Leader at the Mildred Scheel School of Oncology Cologne & Department of Translational Genomics, University Cologne
10/2015 - 08/2020: Postdoctoral research fellow, Molecular Pathology, Institute of Pathology and Department of Translational Genomics, University Cologne (Group of Prof. Dr. Martin Sos)
02/2014 - 09/2015: Clinical fellow, Department of Oncology, University Hospital Bonn
12/2012 - 01/2014: Clinical fellow, Department III of Internal Medicine for Cardiology/Pneumology, University Hospital Cologne
03/2009 - 02/2010: Research fellow with Prof. Dr. Tanguy Seiwert, Institute for Hematology/Oncology, University of Chicago
Honors / Awards / Memberships
01/2021: Associated Research Group at the Center for Molecular Medicine Cologne, University Hospital Cologne
08/2019: Second place in the appointment process for the full professorship position (W2) “Molecular Head and Neck Oncology” at the Department of Otolaryngology, University Hospital Cologne
03/2019 - 03/2021: Memorial-Scholarship, Else Kröner-Fresenius-Stiftung 2015: Gerok-Scholarship, University Hospital Bonn
2009 – 2010: Research scholarship, „Studienstiftung des deutschen Volkes“ 2006 – 2012: Scholar of the „Studienstiftung des deutschen Volkes”
Contact Information
Univ. Prof. Dr. med. Johannes Brägelmann
Professor (W2) for Translational
Oncology
Medical Clinic III Oncology, Hematology & Rheumatoloy
University Hospital Bonn
Department of Translational Genomics
University Hospital Cologne
10 most relevant publications
- Betrancourt A, Cinko MT, Varanda AB, Arias M, Uranga-Murillo I, Peña N, Kaps LM, Chau LF, Buratti B, Brägelmann J, de Miguel D, Becker K, Casper R, Martin R, Alcami A, Ferguson BJ, Pardo J, Rieser E, Walczak H. Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4. Nat Cell Biol. 2026;28(3):608-621. doi:10.1038/s41556-026-01886-z
- Sakthivelu V, Schmitt A, Odenthal F, Ndoci K, Touet M, Shaib AH, Chihab A, Wani GA, Nieper P, Hartmann GG, Pintelon I, Kisis I, Boecker M, Eckert NM, Iannicelli Caiaffa M, Ibruli O, Weber J, Maresch R, Bebber CM, Chitsaz A, Lütz A, Kim Alves Carpinteiro M, Morris KM, Franchino CA, Benz J, Pérez-Revuelta L, Soriano-Campos JA, Huetzen MA, Goergens J, Jevtic M, Jahn-Kelleter HM, Zempel H, Placzek A, Hennrich AA, Conzelmann KK, Tumbrink HL, Hunold P, Isensee J, Werr L, Gaedke F, Schauss A, Minère M, Müller M, Fenselau H, Liu Y, Heimsoeth A, Gülcüler Balta GS, Walczak H, Frezza C, Jachimowicz RD, George J, Schmiel M, Brägelmann J, Hucho T, von Karstedt S, Peifer M, Annibaldi A, Hänsel-Hertsch R, Persigehl T, Grüll H, Sos ML, Reifenberger G, Fischer M, Adriaensen D, Büttner R, Sage J, Brouns I, Rad R, Thomas RK, Anstötz M, Rizzoli SO, Bergami M, Motori E, Reinhardt HC, Beleggia F. Functional synapses between neurons and small cell lung cancer. Nature. 2025;646(8087):1243-1253. doi:10.1038/s41586-025-09434-9
- Pisula JI, Helbig D, Sancéré L, Persa OD, Bürger C, Fröhlich A, Lorenz C, Bingmann S, Niebel D, Drexler K, Landsberg J, Thomas R, Bozek K, Brägelmann J. Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma. NPJ Precis Oncol. 2025;9(1):205. doi:10.1038/s41698-025-00997-4
- Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML*, Berg J*, Brägelmann J*. Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer. Cancer Res. 2023;83(15):2471-2479. doi:10.1158/0008-5472.CAN-22-2605 *co-correspondence
- Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber JP, Altmüller J, Thomas RK, Merkelbach-Bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J*, Scheffler M*, Sos ML*. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021;5(1):102. doi:10.1038/s41698-021-00241-9 *shared senior author
- Brägelmann J*, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, Lohneis P, Gu J, Godfrey LK, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D’Rozario J, Thomas ES, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos ML*. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat Commun. 2021;12(1):5505. doi:10.1038/s41467-021-25728-8 *co-correspondence
- Brägelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, Colombo A, Sanhueza V, Morales E, Rivera MT, de Toro G, Ortega A, Müller B, Gabler F, Scherer D, Waldenberger M, Reischl E, Boekstegers F, Garate-Calderon V, Umu SU, Rounge TB, Popanda O, Lorenzo Bermejo J. Epigenome-Wide Analysis of Methyla-tion Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer. Hepatology. 2021;73(6):2293-2310. doi:10.1002/hep.31585
- Dammert MA*, Brägelmann J*, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019;10(1):3485. doi:10.1038/s41467-019-11371-x *equal contributions
- Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep. 2017;20(12):2833-2845. doi:10.1016/j.celrep.2017.08.082
